Turnstone Biologics (TSBX) Stock Price, News & Analysis

Company Overview

Turnstone Biologics, Inc. (NASDAQ: TSBX) is a clinical-stage biopharmaceutical company pioneering next-generation viral immunotherapies for the treatment of solid tumors. The company’s proprietary platform harnesses engineered oncolytic viruses to selectively infect and lyse cancer cells while simultaneously delivering genetic payloads that stimulate a potent anti-tumor immune response. By combining direct tumor debulking with immune modulation, Turnstone aims to address cancers that have demonstrated resistance to conventional therapies.

Turnstone’s pipeline includes multiple clinical-stage candidates targeting a range of solid tumor indications. Lead programs leverage distinct viral backbones engineered to carry immunostimulatory cytokines, bispecific T-cell engagers or immune checkpoint modulators. These investigational therapies are currently being evaluated in Phase 1/2 trials for hepatocellular carcinoma, pancreatic cancer and virus-associated malignancies such as HPV+ head and neck squamous cell carcinoma. Early-stage assets in preclinical development explore next-generation constructs designed to improve tumor targeting and expand the reach of the platform.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Turnstone Biologics completed its merger with a special purpose acquisition company in early 2021 and began trading on the Nasdaq under the ticker symbol TSBX. The company is led by an experienced management team with deep expertise in oncology drug development, virology and translational medicine. Turnstone collaborates with leading academic institutions and leverages global clinical trial networks to advance its mission of delivering durable, virus-based immunotherapies to patients with high-unmet-need tumors.

Key Stats

• Today's Range: $0.36 to $0.36
• 50-Day Range: $0.35 to $0.37
• 52-Week Range: $0.29 to $0.39
• Volume: N/A
• Average Volume: 350,856 shs
• Market Capitalization: $8.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/08/2025
• Today: 5/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSBX
• CIK: 1764974
• Web: turnstonebio.com
• Phone: 347-897-5988
• Fax: N/A
• Employees: 82
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($2.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -171.86%
• Return on Assets: -128.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.33
• Quick Ratio: 3.70

Sales & Book Value

• Annual Sales: $19.31 million
• Price / Sales: 0.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 23,140,000
• Free Float: 15,713,000
• Market Cap: $8.21 million
• Optionable: Not Optionable
• Beta: 1.36